Johnson & Johnson Launches CereGlide 92, a Large-Bore Neurovascular Catheter, Amid Divestiture Rumors

Feb 13, 2025 22:16 CST Updated 22:16

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson Announces LaunchCereGlide 92Catheter, a next-generation 0.092-inch catheter with the INNERGLIDE 9 delivery assistance device, designed to facilitate the insertion and guidance of interventional devices within the neurovascular system.CereGlide 92It is the latest catheter in Johnson & Johnson's growing catheter portfolio, designed to integrate with stroke solutions such asCereglide71, PROWLER EX and EMBOLRAP III.

Expert Evaluation

"In approximately 50% of mechanical thrombectomy cases, there are challenges posed by vascular tortuosity and other anatomical structures, which may prolong procedure time or render treatment unfeasible. As early users of the Cereglide 92 and Innerglide 9 systems, this extra-large lumen catheter system allows for rapid, seamless access to the M1 segment (proximal middle cerebral artery) and offers flow control advantages, enabling us to quickly achieve patient reperfusion. This brings the benefits of next-generation stroke technology to more patients."

---Brian Jankowitz JFK University Medical Center

Executive Evaluation

"AsCereglide 92With the launch, Johnson & Johnson continues to innovate to help address the access challenges faced by doctors in mechanical thrombectomy.Cereglide 92It is usCereglide"The latest innovation in the ischemic stroke technology suite aims to help doctors treat patients and maximize surgical outcomes, ultimately changing the trajectory of stroke."

---Mark Dickinson Global President of Johnson & Johnson Neurovascular

The middle cerebral artery (MCA) is the larger of the two terminal branches of the internal carotid artery, and ischemia and infarction most commonly affect this area. The middle cerebral artery (MCA) in anatomyGenerally divided into 4 or 5 segments: M1 = horizontal segment, M2 = insular segment, M3 = opercular segment, M4, M5.Collectively referred to as the terminal segment or cortical branches. Among these, 85% of strokes globally are acute ischemic strokes, with the M1 region being the most frequently affected site. Although more than half of ischemic stroke patients who undergo mechanical thrombectomy can regain functional independence, some patients still cannot receive treatment or have poor outcomes due to challenges in vascular access and navigation failures caused by the complex anatomy of the brain.

Therefore, for patients who are difficult to access, a catheter with better tracking performance is required. Johnson & Johnson's new catheterCereGlide 92Not only provides tracking performance, but also features an extra-large inner diameter. This allows doctors toCereGlide 92In thrombectomy, an aspiration catheter can be placed to directly aspirate blood clots or combined with a stent retriever to restore cerebral blood flow.

Recently, it has been circulating overseas that Johnson & Johnson plans toSell for a valuation of $1 billion to $1.5 billionCerenovus. So far, this rumor has not been confirmed by Johnson & Johnson.

CereGlide 92

CereGlide 92Is a neurointerventional device with an inner diameter of 0.092 inches.Catheter, designed to help doctors achieve distal large-bore access and provide flow control function for the M1 segment (proximal middle cerebral artery) during vascular recanalization procedures in patients with acute ischemic stroke. Its large lumen design also offers distal support for various neurovascular devices used in the treatment of aneurysms and other hemorrhagic complications.

CereGlide 92 Advantages

Easy to ReachM1

Paired with INNERGLIDE 9 to reduce step effects and improve M1 delivery consistency.AdoptTruCourse TechnologyEnhanced Catheter Tracking Performance, achieving better M1 passability; compared with competitorsCompared with the Zoom 88 catheter, it has lower tracking force and a longer hydrophilic coating., ensuring smoother delivery.

Large Inner Diameter

It is the neurointerventional catheter with the largest inner diameter (0.092 inches) and smallest distal outer diameter in 8F catheters, specifically designed to reduce M1 blood flow. It supports precise distal positioning and reduces the need for relay with CEREGLIDE 71. It offers optimized length design to ensure efficient M1 delivery.

Excellent Visualization

Real-time visualization of catheter performance in complex anatomical structures achieved through BRITE-LINE technology.Equipped with innovative integrated distal markers to enhance intraoperative positioning accuracy.

Johnson & Johnson

Johnson & Johnson is the world's largest healthcare company, building a world in the prevention, treatment, and curing of complex diseases through medical innovation, where treatments are smarter, less invasive, and solutions more personalized. With its expertise in innovative medicine and medical technology, Johnson & Johnson is uniquely positioned to drive innovation across today’s full spectrum of healthcare solutions, achieve future breakthroughs, and make a profound impact on human health.